0
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to these treatments due to a loss of the antigen that’s being targeted. Now, a new study has found that gene splicing occurring within these cells can cause significant changes in CD20 protein levels that render the therapies ineffective.